scanX
Glenmark Pharmaceuticals
add_icon

Glenmark Pharmaceuticals

2,318.40
-1.60
(-0.07%)
Market Cap
65,425.44 Cr
PE Ratio
36.02
Volume
6,29,081.00
Day High - Low
2,341.60 - 2,307.20
52W High-Low
2,474.00 - 1,792.60
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
65,425.44 Cr
EPS
48.26
PE Ratio
36.02
PB Ratio
6.16
Book Value
372.47
EBITDA
2,035.20
Dividend Yield
0.11 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
11.83
Debt to Equity
0.22
Analyst Rating and Forecast
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+77.78 %
+77.78 %
Hold
Hold+22.22 %
+22.22 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Glenmark Pharma to hold 48th AGM on Sep 11, 20261 day ago
Glenmark Pharmaceuticals Limited announced its 48th Annual General Meeting scheduled for September 11, 2026, via VC/OAVM. The notice was published in Financial Express and Loksatta.
neutral
Glenmark settles US antitrust suit with Humana4 days ago
Glenmark Pharmaceuticals has entered a $15.28 million settlement with Humana to resolve long-standing antitrust litigation. The company states the provision is already accounted for in its financials.
neutral
Glenmark Pharma schedules investor meets9 days ago
Glenmark Pharmaceuticals Limited has announced a schedule of analyst and institutional investor meetings for August and September 2026. The company will hold physical group and one-on-one sessions in Mumbai at four major financial conferences.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,930.00
#1 4,63,071.65
38.47
#1 61,673.90
12.69
#1 11,565
26.53
47.09
Divis Laboratories
8,477.00
2,25,037.72
77.15
11,067.00
13.95
2,568
65.50
71.85
Torrent Pharmaceuticals
4,833.00
1,83,831.78
86.03
13,886.20
20.34
2,138
3.28
45.42
Cipla
1,450.00
1,17,137.57
35.17
29,044.60
2.24
3,870
-39.18
50.74
Zydus Life Science
1,135.20
1,14,227.68
25.48
27,657.90
17.64
5,026
-34.90
50.68
Lupin
2,235.00
1,02,191.47
#1 18.62
29,038.90
#1 26.75
5,356
16.00
30.04
Dr Reddys Laboratories
1,200.00
1,00,160.29
31.62
35,058.60
3.90
4,158
-69.10
49.18
Mankind Pharma
2,425.20
1,00,159.78
48.30
14,636.40
14.85
1,938
29.13
43.34
Laurus Labs
1,787.30
96,488.57
91.23
6,867.80
22.01
890
#1 123.93
61.64
Aurobindo Pharma
1,622.10
93,332.05
25.93
34,145.20
5.56
3,503
25.21
55.68
Growth Rate
Revenue Growth
24.38 %
Net Income Growth
24.94 %
Cash Flow Change
-211.78 %
ROE
-150.71 %
ROCE
146.21 %
EBITDA Margin (Avg.)
-35.42 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1,754
1,631
1,880
1,749
2,211
1,986
2,171
2,478
2,373
2,345
2,253
2,148
2,317
2,268
2,847
2,401
2,565
2,285
2,845
2,672
2,788
2,396
2,879
2,787
2,838
3,005
3,112
3,155
3,068
2,903
3,069
3,272
3,062
3,018
3,281
2,625
3,814
3,255
3,440
3,333
3,232
3,086
6,204
3,933
3,949
3,998
Expenses
1,682
1,288
1,506
1,408
2,003
1,590
1,775
1,770
2,094
1,786
1,868
1,881
1,953
1,819
2,141
2,120
2,199
1,981
2,365
2,296
2,302
1,867
2,400
2,257
2,337
2,391
2,557
2,659
2,638
2,346
2,539
2,626
3,402
2,651
3,071
2,792
3,005
2,656
2,832
2,787
3,068
3,007
5,072
3,215
3,381
3,214
EBITDA
73
343
374
341
208
395
396
708
279
559
385
267
365
449
706
280
366
304
480
376
487
529
480
531
502
614
555
497
430
558
530
646
-340
367
211
-168
808
599
608
546
164
79
1,132
717
568
784
Operating Profit %
4 %
21 %
20 %
19 %
9 %
17 %
18 %
28 %
14 %
23 %
16 %
13 %
13 %
15 %
16 %
16 %
13 %
13 %
14 %
13 %
15 %
19 %
17 %
18 %
17 %
19 %
18 %
15 %
11 %
14 %
15 %
14 %
-15 %
12 %
3 %
-13 %
0 %
18 %
17 %
16 %
5 %
2 %
16 %
17 %
10 %
18 %
Depreciation
65
65
59
52
58
64
69
63
69
78
75
75
74
79
82
83
81
91
94
106
126
113
104
115
111
113
123
119
132
147
146
152
135
142
141
147
151
118
120
123
125
130
141
154
148
173
Interest
40
42
43
47
48
43
63
62
70
71
70
71
74
79
85
89
82
93
90
96
99
94
81
95
83
76
69
67
87
60
83
97
109
112
122
134
149
40
49
52
67
58
67
41
43
54
Profit Before Tax
-10
257
303
274
209
348
315
655
173
444
273
154
249
327
580
154
240
160
347
271
318
358
339
348
338
444
385
343
270
408
337
435
-542
151
-6
-403
555
462
473
456
8
96
967
534
388
643
Tax
-20
75
87
78
60
121
92
178
-11
111
59
49
97
94
166
38
79
51
92
80
98
104
105
100
104
137
110
103
97
197
58
144
-139
-22
56
-72
1,770
122
118
108
4
49
357
131
86
161
Net Profit
11
183
216
196
149
227
224
477
184
333
214
105
152
233
414
116
162
109
256
191
220
254
234
248
234
307
275
240
173
211
279
291
-403
173
-62
-331
-1,214
340
355
348
4
47
610
403
301
483
EPS in ₹
0.39
6.66
7.66
6.95
5.28
8.04
7.92
16.91
6.51
11.81
7.59
3.71
5.37
8.26
14.67
4.12
5.73
3.87
9.06
6.76
7.81
9.00
8.29
8.80
8.29
10.86
9.13
7.86
5.51
6.82
9.23
9.66
-15.18
5.31
-2.90
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
21.63
14.29
10.68
17.11
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
9,688
10,193
11,764
12,595
13,289
14,685
15,604
17,083
19,372
14,359
16,050
19,908
Fixed Assets
2,836
2,594
2,755
3,030
3,670
5,029
5,129
5,887
5,422
4,210
4,487
6,741
Current Assets
5,323
5,904
6,875
6,989
6,697
6,804
7,360
8,282
10,726
7,428
9,296
11,300
Capital Work in Progress
492
543
708
1,122
1,399
1,222
1,382
1,010
1,190
662
835
428
Investments
0
17
16
15
30
25
25
50
45
790
56
3,431
Other Assets
6,359
7,039
8,285
8,429
8,190
8,410
9,068
10,137
12,716
8,697
10,672
0
Total Equity & Liabilities
9,688
10,193
11,764
12,595
13,289
14,685
15,604
17,083
19,372
14,359
16,050
19,908
Current Liabilities
3,711
3,999
2,703
3,288
4,021
4,126
4,201
4,689
5,105
5,819
5,967
6,376
Non Current Liabilities
2,976
2,564
4,569
4,144
3,663
4,489
4,338
2,956
4,427
693
1,234
3,020
Total Equity
3,000
3,629
4,492
5,163
5,605
6,070
7,064
9,438
9,839
7,848
8,849
10,512
Reserve & Surplus
2,973
3,601
4,464
5,135
5,577
6,042
7,036
9,058
9,446
7,820
8,821
10,484
Share Capital
27
28
28
28
28
28
28
28
28
28
28
28
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-31
93
199
177
-297
174
28
272
33
215
17
Investing Activities
-712
-950
-1,001
-1,003
-883
-774
-662
-316
-515
4,387
58
Operating Activities
482
345
657
1,648
1,324
1,392
1,131
1,109
625
-265
-828
Financing Activities
199
699
543
-469
-739
-445
-442
-521
-78
-3,906
787
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
46.63 %
46.63 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.64 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
24.80 %
23.71 %
21.38 %
20.98 %
23.05 %
23.51 %
23.16 %
20.62 %
20.73 %
19.20 %
20.34 %
20.89 %
DIIs
3.82 %
4.94 %
5.09 %
7.08 %
6.62 %
6.01 %
10.64 %
10.69 %
10.41 %
9.11 %
10.32 %
10.92 %
13.36 %
13.92 %
13.21 %
13.85 %
14.60 %
17.64 %
18.61 %
20.09 %
19.29 %
18.60 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
Public / Retail
15.92 %
14.43 %
16.02 %
15.88 %
15.88 %
16.32 %
16.47 %
16.72 %
16.90 %
15.20 %
14.83 %
14.77 %
14.83 %
14.58 %
13.61 %
12.65 %
12.32 %
11.69 %
10.81 %
10.77 %
10.32 %
10.60 %
Others
33.63 %
34.00 %
32.25 %
30.40 %
30.86 %
31.02 %
26.21 %
25.91 %
26.01 %
29.01 %
3.37 %
3.92 %
3.75 %
3.83 %
3.45 %
3.31 %
3.24 %
3.37 %
3.16 %
3.26 %
3.36 %
3.21 %
No of Share Holders
2,50,849
2,75,801
3,29,870
3,17,383
3,10,516
3,12,473
3,13,540
3,00,106
2,85,461
2,36,908
2,32,685
2,09,931
1,99,451
1,92,630
1,93,949
1,95,059
1,92,724
1,90,210
1,98,789
2,01,584
1,96,105
2,11,418

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 2 2 2 2.5 2.5 2.5 2.5 2.5 2.5 5
Dividend Yield (%) 0.38 0.31 0.97 0.54 0.57 0.56 0.26 0.16 0.12 0.22

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Sept 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Sept 2026 2,190.30 2,340.00
31 Aug 2026 DIVIDEND Dividend
₹ 2.50 /share
 31 Aug 2026 2,384.90 2,340.00
10 Sept 2021 DIVIDEND Dividend
₹ 2.50 /share
 08 Sept 2021 606.70 524.55
14 Sept 2022 DIVIDEND Dividend
₹ 2.50 /share
 12 Sept 2022 397.90 393.35
19 Sept 2023 DIVIDEND Dividend
₹ 2.50 /share
 18 Sept 2023 604.10 850.75
29 Sept 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Sept 2023 749.15 776.95
17 Sept 2024 DIVIDEND Dividend
₹ 2.50 /share
 13 Sept 2024 1,027.60 1,741.85
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 27 Sept 2024 1,684.85 1,676.95
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Nov 2024 1,673.95 1,539.40
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Feb 2025 1,436.30 1,411.20
23 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 May 2025 1,398.20 1,431.10
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Aug 2025 2,067.80 2,029.30
15 Sept 2025 DIVIDEND Dividend
₹ 2.50 /share
 15 Sept 2025 1,431.10 2,132.50
26 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 26 Sept 2025 1,941.60 2,031.05
03 Oct 2025 DIVIDEND Dividend
₹ 2.50 /share
 03 Oct 2025 2,031.05 1,958.65
14 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Nov 2025 1,890.35 1,876.40
30 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 30 Jan 2026 2,000.60 1,986.75
29 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2026 2,340.45 2,384.90
31 Jul 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jul 2026 2,305.10 2,190.30

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report 3 days ago
Business Responsibility and Sustainability Reporting (BRSR)3 days ago
Reg. 34 (1) Annual Report.3 days ago
Notice Of The 48Th Annual General Meeting For The Financial Year 2025-263 days ago
Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 20155 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication9 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 03, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2026
Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - List Of OfficialsJul 31, 2026
Intimation Of Record Date For DividendJul 31, 2026
Board Meeting Outcome for Board Meeting Outcome - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026Jul 31, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 25, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2026
Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of Glenmark Pharmaceuticals Limited For The Quarter Ended June 30 2026Jul 15, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 06, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 02, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 30, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 25, 2026
Closure of Trading WindowJun 25, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 17, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 11, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJun 09, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 05, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 01, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2026
Transfer Of Companys Nebulizer BrandMay 29, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
Corporate Action-Board to consider DividendMay 29, 2026
Board Meeting Outcome for Audited Financial Results And Recommendation Of Final DividendMay 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 23, 2026
Settlement Agreement: Pursuant To Regulation 30 Of The SEBI (LODR) Regulations 2015May 23, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2026
Closure of Trading WindowMay 19, 2026
Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results And Recommending Dividend If Any On Equity Shares For The Year Ended March 31 2026.May 19, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 18, 2026
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 30, 2026
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 09, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Motilal Oswal BSE Midcap 150 Momentum 30 Index Fund Direct-Growth
3.40%
5786
3.40%
3.40%
Franklin India Multi-Factor Fund Direct-Growth
0.74%
5041
0.17%
0.29%
Mirae Asset Nifty200 Momentum 30 Plus 8-13yr G-Sec 75:25 Index Fund Direct-Growth
1.21%
683
1.21%
1.21%
JioBlackRock Sector Rotation Fund Direct-Growth
0.26%
673
0.09%
0.10%
SBI Nifty200 Momentum 30 Index Fund Direct-Growth
1.63%
-650
0.05%
0.17%
Tata Nifty Midcap 150 Index Fund Direct-Growth
0.81%
535
-0.01%
-0.04%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.80%
319
-0.01%
-0.05%
Zerodha Life Cycle Fund 2041 Direct-Growth
0.31%
201
0.31%
0.31%
Zerodha Life Cycle Fund 2036 Direct-Growth
0.26%
179
0.26%
0.26%
AlphaGrep Multi Asset Allocation Fund Direct-Growth
0.07%
167
0.07%
0.07%
Kotak Nifty Alpha 50 Index Fund Direct-Growth
1.83%
117
-0.03%
-0.11%
Aditya Birla Sun Life BSE 500 Momentum 50 Index Fund Direct-Growth
1.98%
116
0.02%
0.53%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.28%
-91
-0.01%
0.05%
DSP Nifty Healthcare Index Fund Direct-Growth
2.92%
84
-0.13%
-0.36%
Kotak Nifty Midcap 150 Index Fund Direct-Growth
0.81%
71
-0.01%
-0.04%
Edelweiss Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.28%
46
0.00%
-0.03%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.40%
39
-0.01%
-0.02%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.57%
-21
-0.03%
-0.03%
Kotak Nifty500 Momentum 50 Index Fund Direct-Growth
1.57%
21
0.03%
0.41%
Groww Nifty Midcap 150 Index Fund Direct-Growth
0.80%
-21
-0.01%
-0.05%
DSP Nifty Midcap 150 Index Fund Direct-Growth
0.81%
20
0.00%
-0.04%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.16%
-8
0.00%
-0.01%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.53%
-3
0.00%
-0.03%
DSP Nifty 500 Index Fund Direct-Growth
0.17%
1
0.00%
-0.01%
JioBlackRock Arbitrage Fund Direct-Growth
0.00%
0
0.00%
-0.02%

Technical Indicators

RSI(14)
Neutral
61.19
ATR(14)
Less Volatile
51.75
STOCH(9,6)
Overbought
84.91
STOCH RSI(14)
Overbought
99.46
MACD(12,26)
Bullish
9.25
ADX(14)
Weak Trend
13.19
UO(9)
Bearish
52.46
ROC(12)
Uptrend And Accelerating
2.51
WillR(14)
Overbought
-12.92
Bearish
5
Neutral
2
Bullish
2

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several...more
Website
https://www.glenmarkpharma.com
Chairperson NameGlenn Saldanha
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104